{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:09:17Z","timestamp":1781154557535,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T00:00:00Z","timestamp":1437955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Cancer Therapy Evaluation Program of National Cancer Institute, USA"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    We conducted a phase\n                    <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                    study of the\n                    <jats:styled-content style=\"fixed-case\">AKT<\/jats:styled-content>\n                    inhibitor,\n                    <jats:styled-content style=\"fixed-case\">MK<\/jats:styled-content>\n                    2206 in patients with relapsed or refractory lymphoma of any histology excluding Burkitt lymphoma or lymphoblastic lymphoma.\n                    <jats:styled-content style=\"fixed-case\">MK<\/jats:styled-content>\n                    \u20102206 was administered orally at 200\u00a0mg once weekly in 28\u2010d cycles up to 12 cycles in the absence of progression or significant toxicity. The dose was adjusted based on tolerance. A total of 59 patients were enrolled. The final doses patients received were 300\u00a0mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a033), 250\u00a0mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a02), 200\u00a0mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a016) and 135\u00a0mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a08). Based on intent\u2010to\u2010treat analysis, objective response was observed in 8 (14%) patients (2 complete response and 6 partial response), with median response duration of 5\u00b78\u00a0months. The overall response rate was 20% in 25 patients with classical Hodgkin lymphoma. Rash was the most common toxicity (any grade 53%, Grade 3 in 15%) and was observed in a dose\u2010dependent manner. The correlative cytokine analysis showed paradoxical increase in several cytokines, which may be explained by negative feedback mechanism induced by the on\u2010target effect of\n                    <jats:styled-content style=\"fixed-case\">AKT<\/jats:styled-content>\n                    inhibitor. Our data demonstrate that\n                    <jats:styled-content style=\"fixed-case\">MK<\/jats:styled-content>\n                    2206 has a favourable safety profile with a modest activity in patients with relapsed Hodgkin lymphoma. The future studies should explore mechanism\u2010based combinations (clinicaltrials.gov\n                    <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n                    01258998).\n                  <\/jats:p>","DOI":"10.1111\/bjh.13603","type":"journal-article","created":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T02:37:44Z","timestamp":1437964664000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma"],"prefix":"10.1111","volume":"171","author":[{"given":"Yasuhiro","family":"Oki","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Copeland","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas, M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.123"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3037","article-title":"Phase I clinical trial of an allosteric AKT inhibitor, MK\u20102206, using a once weekly (QW) dose regimen in patients with advanced solid tumors","volume":"29","author":"Biondo A.","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.87.87","article-title":"Preliminary results of a phase II study of single agent Bay 80\u20106946, a novel PI3K inhibitor, in patients with relapsed\/refractory, indolent or aggressive lymphoma","volume":"122","author":"Dreyling M.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2664"},{"key":"e_1_2_8_7_1","article-title":"Final report of a phase I study of idelalisib (GS\u20101101) a selective inhibitor of PI3Kd, in patients with relapsed or refractory CLL","volume":"31","author":"Flinn I.W.","year":"2013","journal-title":"Hematological Oncology"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.677.677","article-title":"Preliminary safety and efficacy of IPI\u2010145, a potent inhibitor of phosphoinositide\u20103\u2010kinase\u2010\u03b4,\u03b3, in patients with chronic lymphocytic leukemia","volume":"122","author":"Flinn I.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.1.131"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.08.008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1012"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI\u2010145), a phosphoinositide\u20103\u2010kinase\u2010d,? inhibitor, shows activity in patients with relapsed\/refractory T\u2010cell lymphoma","volume":"124","author":"Horwitz S.M.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07091"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8028","article-title":"Everolimus (EVE) for relapsed\/refractory classical Hodgkin lymphoma (cHL): open\u2010label, single\u2010arm, phase II study","volume":"30","author":"Johnston P.B.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2740.2740","article-title":"Everolimus for relapsed\/refractory classical hodgkin lymphoma: multicenter, open\u2010label, single\u2010arm, phase 2 study","volume":"120","author":"Johnston P.B.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1978"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3321"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:APPT.0000045801.15585.dd"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1407"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053173"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.10"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2813"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5263"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0764"},{"key":"e_1_2_8_31_1","article-title":"Pilot phase 2 study of idelalisib, a selective inhibitor of PI3Kd, in patients with heavily pretreated hodgkin lymphoma (HL)","volume":"31","author":"Younes A.","year":"2013","journal-title":"Hematological Oncology"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1718.1718","article-title":"An open\u2010label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B\u2010cell lymphoma, mantle cell lymphoma or follicular lymphoma","volume":"124","author":"Younes A.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.245"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25005"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13603","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:58:37Z","timestamp":1696334317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,27]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/bjh.13603"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13603","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725675529.793539755","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,27]]},"assertion":[{"value":"2015-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}